• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Mirati - oncology?









































You’d think but nah. Let’s screw up what works. Lay off everyone in May and have no clue who is taking the work is chaos
when they said that “we dont want to disrupt your amazing job” but literally created a clone team with their own internal people to co-lead…you know is time to start updating your resume
 
















Mirati was full of BMS failures, so it's a "Turkey shoot" us. We knew exactly who to shit can (practically all of them!!!).

Amgen completely schooled you. Go home, your done!!!